According to the National Institute of Mental Health (NIMH), major depression is one of the most common mental disorders in the United States. In 2013, an estimated 15.7 million individuals aged 18 or over – roughly 6.7 percent of all … Continue reading →

Millions of people around the world suffer from depression, which ranges from short-lived emotional responses to something as severe as suicide, positioning the mental disease as the leading cause of disability worldwide and a dire global health concern. While recommended … Continue reading →

Unexpected cardiotoxicity, which damages the heart muscles, is among the most prevalent reasons for failure of both drugs and drug candidates. VistaGen Therapeutics, Inc. (OTCQB: VSTA), through its customized cellular assay system, CardioSafe 3D™, is working to enhance current testing … Continue reading →

VistaGen Therapeutics was founded in the late 1990s by a team of scientists believing that better cells lead to better medicine. In the years since, this California-based clinical-stage biopharmaceutical company also has focused on developing groundbreaking medicine for depression and … Continue reading →

According to a report published in September of 2014 by Transparency Market Research on anxiety disorder and depression treatments, the global market for depression treatment was around $22.5 billion in 2013 and is estimated to be running at around a … Continue reading →

If you think depression only affects the individual suffering from the disorder, or even their friends and family, think again. As a nation, depression affects all of us in one way or another. According to a report from the Journal … Continue reading →

Ketamine has been shown as an extremely effective treatment for patients suffering from major depressive disorder (MDD). Unfortunately, its prospects for widespread therapeutic use are exceptionally limited because of its high potential for abuse, dissociative and psychosis-like side effects, and … Continue reading →

VistaGen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative medicine for depression and conditions associated with the central nervous system, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), … Continue reading →

Believing that better cells lead to better medicine, VistaGen Therapeutics has been applying pluripotent stem cell technology toward drug rescue, predictive toxicology and drug metabolism screening. VistaGen’s activities are guided by the belief that the key to making better cells … Continue reading →

Since inception, VistaGen Therapeutics has focused on creating human cell-based biological assay systems that reveal the potential toxic effects of new drug candidates before they are tested in animals or humans. Today’s next-generation biological assays are delivering needed preclinical human … Continue reading →